Clinical Trial Update: A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating paclitaxel with reparixin vs placebo in metastatic triple-negative breast cancer; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Reparixin (reparixin)

Snippet

Sponsor: Dompé Farmaceutici S.p.A | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-06-02